FATE THERAPEUTICS INC Cash and Restricted Cash
FATE THERAPEUTICS INC (FATE) had Cash and Restricted Cash of $36.39 million as of 2018-06-30, per its 10-Q filed 2018-08-06.
Discontinued › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2018-08-06
- 2018-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $36.39M.
- 2018-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $33.03M.
- 2017-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $89.07M.
- 2017-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $40.73M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2018-06-30 | $36.39M 10-Q · filed 2018-08-06 |
| 2018-03-31 | $33.03M 10-Q · filed 2018-05-10 |
| 2017-12-31 | $89.07M 10-Q · filed 2018-05-10 |
| 2017-03-31 | $40.73M 10-Q · filed 2018-05-10 |
| 2016-12-31 | $88.73M 10-Q · filed 2018-05-10 |
| 2015-12-31 | $64.93M 10-K · filed 2018-03-05 |
| 2014-12-31 | $49.22M 10-K · filed 2018-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |